Twist2 contributes to cisplatin-resistance of ovarian cancer through the AKT/GSK-3β signaling pathway

Oncology Letters

Volumn 7, Issue 4, 2014, Pages 1102-1108

  Wang, Tian ^a   Li, Yan ^a   Tuerhanjiang, Abidan ^a   Wang, Wenwen ^a   Wu, Zhangying ^a   Yuan, Ming ^a   Maitituoheti, Mayinuer ^a   Wang, Shixuan ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

AKT GSK 3 pathway; Chemoresistance; Cisplatin; Ovarian cancer; Twist2

Indexed keywords

CISPLATIN; GLYCOGEN SYNTHASE KINASE 3BETA; PROTEIN KINASE B; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR TWIST2; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL GROWTH; CELL VIABILITY ASSAY; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; MTT ASSAY; OVARY CANCER; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84896737074     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.1816     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
2. Fraser M, Leung B, Jahani-Asl A, Yan X, Thompson WE and Tsang BK: Chemoresistance in human ovarian cancer: the role of apoptotic regulators. Reprod Biol Endocrinol 1: 66, 2003.
3. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C and Thun MJ: Cancer statistics, 2006. CA Cancer J Clin 56: 106-130, 2006.
4. Yang X, Xing H, Gao Q, Chen G, Lu Y, Wang S and Ma D: Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells. Gynecol Oncol 97: 413-421, 2005.
5. Yu H, Jin GZ, Liu K, Dong H, Yu H, Duan JC, Li Z, Dong W, Cong WM and Yang JH: Twist2 is a valuable prognostic biomarker for colorectal cancer. World J Gastroenterol 19: 2404-2411, 2013.
6. Gasparotto D, Polesel J, Marzotto A, Colladel R, Piccinin S, Modena P, Grizzo A, Sulfaro S, Serraino D, Barzan L, Doglioni C and Maestro R: Overexpression of TWIST2 correlates with poor prognosis in head and neck squamous cell carcinomas. Oncotarget 2: 1165-1175, 2011.
7. Zhou C, Liu J, Tang Y, Zhu G, Zheng M, Jiang J, Yang J and Liang X: Coexpression of hypoxia-inducible factor-2α, TWIST2, and SIP1 may correlate with invasion and metastasis of salivary adenoid cystic carcinoma. J Oral Pathol Med 41: 424-431, 2012.
8. Li Y, Wang W, Wang W, Yang R, Wang T, Su T, Weng D, Tao T, Li W, Ma D and Wang S: Correlation of TWIST2 up-regulation and epithelial-mesenchymal transition during tumorigenesis and progression of cervical carcinoma. Gynecol Oncol 124: 112-118, 2012.
9. Koh HS, Lee C, Lee KS, Park EJ, Seong RH, Hong S and Jeon SH: Twist2 regulates CD7 expression and galectin-1-induced apoptosis in mature T-cells. Mol Cells 28: 553-558, 2009.
10. Ansieau S, Bastid J, Doreau A, Morel AP, Bouchet BP, Thomas C, Fauvet F, Puisieux I, Doglioni C, Piccinin S, Maestro R, Voeltzel T, Selmi A, Valsesia-Wittmann S, Caron de Fromentel C and Puisieux A: Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell 14: 79-89, 2008.
11. Acloque H, Adams MS, Fishwick K, Bronner-Fraser M and Nieto MA: Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest 119: 1438-1449, 2009.
12. Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell 144: 646-674, 2011.
13. Singh A and Settleman J: EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29: 4741-4751, 2010.
14. Johnson-Holiday C, Singh R, Johnson EL, Grizzle WE, Lillard JW Jr and Singh S: CCR9-CCL25 interactions promote cisplatin resistance in breast cancer cell through Akt activation in a PI3K-dependent and FAK-independent fashion. World J Surg Oncol 9: 46, 2011.
15. Ali AY, Farrand L, Kim JY, Byun S, Suh JY, Lee HJ and Tsang BK: Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrum. Ann N Y Acad Sci 1271: 58-67, 2012.
16. Cheng JQ, Jiang X, Fraser M, Li M, Dan HC, Sun M and Tsang BK: Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway. Drug Resist Updat 5: 131-146, 2002.
17. Mao Y, Zhang N, Xu J, Ding Z, Zong R and Liu Z: Significance of heterogeneous Twist2 expression in human breast cancers. PLoS One 7: e48178, 2012.
18. Tiwari N, Gheldof A, Tatari M and Christofori G: EMT as the ultimate survival mechanism of cancer cells. Semin Cancer Biol 22: 194-207, 2012.
19. Smit MA, Geiger TR, Song JY, Gitelman I and Peeper DS: A Twist-Snail axis critical for TrkB-induced epithelial-mesenchymal transition-like transformation, anoikis resistance, and metastasis. Mol Cell Biol 29: 3722-3737, 2009.
20. Tsai CC, Chen YJ, Yew TL, Chen LL, Wang JY, Chiu CH and Hung SC: Hypoxia inhibits senescence and maintains mesenchymal stem cell properties through down-regulation of E2A-p21 by HIF-TWIST. Blood 117: 459-469, 2010.
21. Li QQ, Xu JD, Wang WJ, Cao XX, Chen Q, Tang F, Chen ZQ, Liu XP and Xu ZD: Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res 15: 2657-2665, 2009.
22. Bialek P, Kern B, Yang X, Schrock M, Sosic D, Hong N, Wu H, Yu K, Ornitz DM, Olson EN, Justice MJ and Karsenty G: A twist code determines the onset of osteoblast differentiation. Dev Cell 6: 423-435, 2004.
23. Tsuji T, Ibaragi S, Shima K, Hu MG, Katsurano M, Sasaki A and Hu GF: Epithelial-mesenchymal transition induced by growth suppressor p12CDK2-AP1 promotes tumor cell local invasion but suppresses distant colony growth. Cancer Res 68: 10377-10386, 2008.
24. Tukel T, Šošić D, Al-Gazali LI, Erazo M, Casasnovas J, Franco HL, Richardson JA, Olson EN, Cadilla CL and Desnick RJ: Homozygous nonsense mutations in TWIST2 cause Setleis syndrome. Am J Hum Genet 87: 289-296, 2010.
25. Franco HL, Casasnovas J, Rodríguez-Medina JR and Cadilla CL: Redundant or separate entities?-roles of Twist1 and Twist2 as molecular switches during gene transcription. Nucleic Acids Res 39: 1177-1186, 2011.
26. Perez RP: Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 34: 1535-1542, 1998.
27. Aoki K, Ogawa T, Ito Y and Nakashima S: Cisplatin activates survival signals in UM-SCC-23 squamous cell carcinoma and these signal pathways are amplified in cisplatin-resistant squamous cell carcinoma. Oncol Rep 11: 375-379, 2004.
28. Testa JR and Bellacosa A: AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 98: 10983-10985, 2001.
29. Simon D, Herva ME, Benitez MJ, Garrido JJ, Rojo AI, Cuadrado A, Torres JM and Wandosell F: Dysfunction of the PI3K-Akt-GSK-3 pathway is a common feature in cell culture and in vivo models of prion disease. Neuropathol Appl Neurobiol: Jun 6, 2013 (Epub ahead of print). doi: 10.1111/nan.12066.
30. el-Arafa SA, Zhu Q, Barakat BM, Wani G, Zhao Q, El-Mahdy MA and Wani AA: Tangeretin sensitizes cisplatin-resistant human ovarian cancer cells through downregulation of phosphoinositide 3-kinase/Akt signaling pathway. Cancer Res 69: 8910-8917, 2009.
31. Chen R, Yang Q and Lee JD: BMK1 kinase suppresses epithelial-mesenchymal transition through the Akt/GSK3β signaling pathway. Cancer Res 72: 1579-1587, 2012.
32. Maseki S, Ijichi K, Tanaka H, Fujii M, Hasegawa Y, Ogawa T, Murakami S, Kondo E and Nakanishi H: Acquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK-3β/snail signalling pathway. Br J Cancer 106: 1196-1204, 2012.